financetom
Business
financetom
/
Business
/
GRAPHIC-Tesla's bumpy ride, captured in five charts
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GRAPHIC-Tesla's bumpy ride, captured in five charts
Apr 5, 2024 9:07 AM

April 5 (Reuters) - Tesla's reported move to

scrap plans for a low-cost car marks the latest disappointment

for investors who have dumped shares of the automaker this year

on worries over slowing demand, an aging vehicle line-up and

rising Chinese competition.

Reuters reported earlier on Friday that Tesla has canceled

the long-promised inexpensive car but will continue developing

self-driving robotaxis on the same small-vehicle platform.

Shares of the electric-vehicle maker fell 4.7% on the news.

They were already down nearly 32% this year, as of last close,

making them among the worst performers on the S&P 500 index.

Here are five charts on Tesla's rocky ride in 2024:

MAGNIFICENT SEVEN LAGGARD

This year's slump in Tesla stock has threatened its place in

an elite grouping of companies that powered a surge in U.S.

markets in recent years, several market experts have said.

The so-called "Magnificent Seven" consists of Apple ( AAPL )

, Microsoft ( MSFT ), Amazon.com ( AMZN ), Alphabet

, Meta Platforms ( META ), Nvidia ( NVDA ) and Tesla.

But Tesla is no longer looking so magnificent, and some

analysts say AI-linked names such as Advanced Micro Devices ( AMD )

or Broadcom ( AVGO ) might be more appropriate as part

of that group of big market gainers.

SINKING MARKET VALUE

Tesla has lost more than $250 billion in market value this

year. While it remains the world's most valuable automaker,

Toyota Motor ( TM ) is slowly narrowing the gap as the

Japanese company rides a boom in demand for hybrid vehicles.

Toyota's ( TM ) shares have risen nearly 40% this year, pushing its

market value up by around $80 billion. But some analysts have

warned Toyota ( TM ) remains a laggard in pure battery EVs, which are

widely viewed as the long-term future of the auto industry.

At its peak in late 2021, Tesla's market cap surpassed more

than $1 trillion in value, but the stock has lost more than half

its value since then.

DELIVERIES SLUMP

Tesla posted a decline in quarterly deliveries for the first

time since the second quarter of 2020, when the COVID-19

pandemic shut down a significant amount of production at its

factories.

Analysts have said that the effects of Tesla's

margin-sapping price cuts to boost demand have been waning with

the company producing many more vehicles than it is handing over

to customers.

GLOBAL AUTOMAKERS SALES TOWER TESLA'S

Automakers such as Volkswagen, Toyota ( TM ) and Honda sold far

more vehicles than Tesla in 2023, yet the EV maker's market

capitalization eclipses that of Toyota ( TM ), Mercedes-Benz and

Porsche combined.

MUSK'S PERSONA POLARIZES WOULD-BE BUYERS

The number of would-be Tesla buyers in the U.S. is

shrinking, according to a survey by market intelligence firm

Caliber, which attributed the drop in part to CEO Elon Musk's

polarizing persona.

Caliber's "consideration score" for Tesla fell to 31% in

February, less than half its high of 70% in November 2021 when

it started tracking consumer interest in the brand.

Reuters spoke to five marketing, polling and car experts who

said controversies surrounding Musk's increasingly right-wing

politics and public statements are weighing on Tesla's brand and

demand.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
OR Royalties Reports Project Advances at Cascabel, Cariboo and Marimaca, Expects Further 2025 Portfolio Growth
OR Royalties Reports Project Advances at Cascabel, Cariboo and Marimaca, Expects Further 2025 Portfolio Growth
Sep 11, 2025
08:39 AM EDT, 09/11/2025 (MT Newswires) -- OR Royalties ( OR ) reported Thursday positive updates on some of its assets. SolGold continues to advance the Cascabel project in Ecuador, with first production scheduled as early as 2028. A project execution plan has been delivered while work continues on an environmental impact assessment, OR said. OR's interest in Cascabel include...
Kazia Says Paxalisib Disrupts Tumor Cell Clusters in HER2-Positive Breast Cancer Study
Kazia Says Paxalisib Disrupts Tumor Cell Clusters in HER2-Positive Breast Cancer Study
Sep 11, 2025
08:42 AM EDT, 09/11/2025 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Thursday that paxalisib monotherapy completely disrupted large circulating tumor cell clusters in blood samples from stage IV HER2-positive breast cancer patients in an ex vivo study conducted by QIMR Berghofer. The company said the treatment also showed statistically significant reduction in single circulating tumor cells, which are...
Foraco to Repurchase Up to 1 Million Shares Under New Normal Course Issuer Bid
Foraco to Repurchase Up to 1 Million Shares Under New Normal Course Issuer Bid
Sep 11, 2025
08:41 AM EDT, 09/11/2025 (MT Newswires) -- Foraco International ( FRACF ) Thursday said the Toronto Stock Exchange has accepted its notice to repurchase up to 1 million shares under a normal course issuer bid. The bid will start Sept. 15 and run for one year. Foraco ( FRACF ) repurchased 956,100 shares under its previous NCIB at a weighted...
Amneal Pharmaceuticals Wins US FDA Approval for Generic Version of Narcolepsy Drug Xyrem
Amneal Pharmaceuticals Wins US FDA Approval for Generic Version of Narcolepsy Drug Xyrem
Sep 11, 2025
08:42 AM EDT, 09/11/2025 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) said Thursday that the US Food and Drug Administration has approved its generic version of sodium oxybate oral solution, referencing Jazz Pharmaceuticals' ( JAZZ ) Xyrem. The drug is used to treat cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy, the company said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved